Meeting
2019 ASCO Annual Meeting
Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial.
Authors
Ye Guo
Shanghai East Hospital, Tongji University, Shanghai, China
Ye Guo , Myung-Ju Ahn , Anthony T. C. Chan , Cheng-Hsu Wang , Jin Hyoung Kang , Sung-Bae Kim , Maximino De Guzman Bello III, Rajendra Singh Arora , Qingyuan Zhang , Xiaohui He , Ping Li , Arunee Dechaphunkul , Vijay Kumar , Krishna Kamble , Wei Li , Alaa Kandil , Ezra E.W. Cohen , Yuan Geng , Lef Zografos , Ping Zhang Tang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01856478
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6024)
DOI
10.1200/JCO.2019.37.15_suppl.6024
Abstract #
6024
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1).
First Author: Ezra E. W. Cohen
Poster
2019 ASCO Annual Meeting
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
First Author: Lisa F. Licitra
Poster
2012 ASCO Annual Meeting
LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy.
First Author: Jean-Pascal H. Machiels
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized phase III study comparing 2-weekly docetaxel, cisplatin and 5-FU (bDCF) with cisplatin and 5-FU (CF) in patients with metastatic or recurrent esophageal cancer: JCOG1314 (MIRACLE).
First Author: Takahiro Tsushima